The CIDD Clinical Trials Program<\/strong> was founded in 2018 by Mark Shen, PhD,<\/a> and a team of interdisciplinary clinicians and researchers. Since then, the program has grown exponentially and conducts clinical trials and observational research on a range of genetic and neurodevelopmental conditions. The CIDD Clinical Trials Program supports industry, federal, foundation, and investigator-initiated research, working collaboratively with investigators and funders to conduct innovative clinical trials effectively while prioritizing patient care. Our team consists of specialized investigators, research coordinators, and administrative support to assist with regulatory compliance, finances, and quality oversight.<\/p>\n The Angelman Syndrome Research Program<\/strong> was founded by an interdisciplinary team of researchers focused on improving the lives of individuals with Angelman syndrome. Our Angelman syndrome research includes both basic research and drug discovery projects, with the expectation that our innovative discoveries will lead to new therapeutics for Angelman syndrome.<\/p>\n We encourage you to explore below to learn more about our research teams, and to choose a research study you are interested in joining.<\/p>\n <\/p>\n For questions about the Angelman Syndrome Natural History Study<\/strong> or the LADDER Learning Network<\/strong>, contact Margaret DeRamus<\/a>.<\/p>\n For questions about the CIDD Clinical Trials Program<\/strong>, contact Hannah Riehl<\/a>.<\/p>\n For questions about the Brain Development Study of Infants with Angelman Syndrome & Fragile X Syndrome<\/strong>, contact shenlab@med.unc.edu<\/a>.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":" The CIDD Clinical Trials Program was founded in 2018 by Mark Shen, PhD, and a team of interdisciplinary clinicians and researchers. Since then, the program has grown exponentially and conducts clinical trials and observational research on a range of genetic and neurodevelopmental conditions. The CIDD Clinical Trials Program supports industry, federal, foundation, and investigator-initiated research, … Read more<\/a><\/p>\n","protected":false},"author":79967,"featured_media":0,"parent":27,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"layout":"","cellInformation":"","apiCallInformation":"","footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-30","page","type-page","status-publish","hentry","odd"],"acf":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/cidd\/wp-json\/wp\/v2\/pages\/30","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/cidd\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.unc.edu\/cidd\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/cidd\/wp-json\/wp\/v2\/users\/79967"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/cidd\/wp-json\/wp\/v2\/comments?post=30"}],"version-history":[{"count":5,"href":"https:\/\/www.med.unc.edu\/cidd\/wp-json\/wp\/v2\/pages\/30\/revisions"}],"predecessor-version":[{"id":2062,"href":"https:\/\/www.med.unc.edu\/cidd\/wp-json\/wp\/v2\/pages\/30\/revisions\/2062"}],"up":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/cidd\/wp-json\/wp\/v2\/pages\/27"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/cidd\/wp-json\/wp\/v2\/media?parent=30"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nAngelman Syndrome Research Program<\/h2>\n
Contact Us<\/h3>\n